Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Compare Best Stocks
Custom Search Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search
Updated Jan 12, 2024
| LSTA | LISATA THERAPEUTICS, INC. | -1.03K | $2.99 | -$3.07K | Jan 12, 2024 | Tax | -0.58% | 174.77K | Chief Executive Officer | Jan 11 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | 117.48K | $3.07 | -$72.15K | Jan 11, 2024 | Grant | 111.56% | 222.79K | Chief Executive Officer | Jan 9 - Jan 10 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | -397.00 | $3.65 | -$1.45K | Jan 17, 2023 | Tax | -0.41% | 96.54K | Chief Executive Officer | Jan 13 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | -1.03K | $3.20 | -$3.30K | Jan 12, 2023 | Tax | -1.05% | 96.94K | Chief Executive Officer | Jan 11 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | 78.69K | $3.06 | -$34.62K | Jan 11, 2023 | Grant | 159.65% | 127.97K | Chief Executive Officer | Jan 9 - Jan 10 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | 80.26K | $0.50 | $40.13K | Sep 2, 2022 | Grant | 12.18% | 739.44K | Chief Executive Officer | Sep 1 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | -13.08K | $0.81 | -$10.64K | Jan 18, 2022 | Tax | -2.03% | 631.07K | Chief Executive Officer | Jan 13 - Jan 14 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | 527.85K | $0.91 | -$66.21K | Jan 12, 2022 | Grant | 166.88% | 844.15K | Chief Executive Officer | Jan 10 - Jan 11 | — | View | |
| PALI | Seneca Biopharma, Inc. | 6.00K | — | — | Apr 26, 2021 | Grant | — | 6.00K | — | Apr 1 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | 4.85K | $1.55 | -$52.99K | Jan 15, 2021 | Grant | 1.65% | 299.51K | Chief Executive Officer | Jan 13 - Jan 14 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | 157.65K | $1.59 | -$33.99K | Jan 12, 2021 | Grant | 80.03% | 354.65K | Chief Executive Officer | Jan 11 | — | View | |
| PALI | Seneca Biopharma, Inc. | 6.00K | — | — | Apr 7, 2020 | Grant | — | 6.00K | — | Apr 3 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | 52.50K | — | — | Mar 3, 2020 | Grant | — | 52.50K | — | Feb 28 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | 102.37K | $3.33 | -$42.06K | Jan 15, 2020 | Grant | 66.91% | 255.38K | Chief Executive Officer | Jan 13 - Jan 14 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | -4.52K | $2.83 | -$12.80K | Jan 9, 2020 | Tax | -2.87% | 153.01K | Chief Executive Officer | Jan 8 | — | View | |
| PALI | Neuralstem, Inc. | 10.11K | — | — | Oct 11, 2019 | Grant | — | 10.11K | — | Jul 1 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | — | $1.95 | $65.00K | Oct 11, 2019 | Options | — | 200.08K | — | Oct 9 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | — | — | — | Sep 10, 2019 | Options | — | 166.75K | — | Sep 6 | — | View | |
| PALI | Neuralstem, Inc. | 187.51K | — | — | Jul 3, 2019 | Grant | — | 187.51K | — | Jul 1 | — | View | |
| PALI | Neuralstem, Inc. | — | — | — | Jun 27, 2019 | — | — | — | — | Jan 13 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | 40.00K | — | — | Jun 27, 2019 | Grant | — | 40.00K | — | Jun 25 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | — | — | — | Jun 24, 2019 | Options | — | 166.33K | — | Jun 21 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | — | $1.77 | $35.40K | Apr 1, 2019 | Options | — | 158.00K | — | Mar 29 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | 111.70K | — | — | Jan 16, 2019 | Grant | 100.90% | 222.41K | Chief Executive Officer | Jan 14 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | -4.48K | $4.64 | -$20.78K | Jan 10, 2019 | Tax | -3.89% | 110.71K | Chief Executive Officer | Jan 8 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | 2.08K | — | — | Sep 10, 2018 | Grant | — | 2.08K | — | Sep 6 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | — | — | — | Jun 29, 2018 | Options | — | 138.00K | — | Jun 27 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | 41.67K | — | — | Jun 26, 2018 | Grant | — | 41.67K | — | Jun 21 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | 17.21K | $8.64 | $148.69K | Jun 21, 2018 | Grant | 18.66% | 109.45K | Chief Executive Officer | Jun 20 | — | View | |
| EYPT | EyePoint Pharmaceuticals, Inc. | — | $1.13 | $135.60K | Apr 24, 2018 | Options | — | 120.50K | — | Apr 20 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | 33.30K | — | — | Apr 10, 2018 | Grant | — | 33.30K | Chief Executive Officer | Apr 6 | — | View | |
| LSTA | Caladrius Biosciences, Inc. | 78.84K | — | — | Jan 10, 2018 | Grant | 236.00% | 112.24K | Chief Executive Officer | Jan 8 | — | View | |
| EYPT | pSivida Corp. | 37.50K | — | — | Dec 19, 2017 | Grant | — | 37.50K | — | Dec 15 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | -17.78K | $5.13 | -$91.20K | May 22, 2017 | Tax | -23.92% | 56.55K | Chief Executive Officer | May 18 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | -690.00 | $4.74 | -$3.27K | Apr 27, 2017 | Tax | -0.92% | 74.33K | Chief Executive Officer | Apr 25 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | -761.00 | $3.87 | -$2.95K | Jan 27, 2017 | Tax | -1.00% | 75.02K | Chief Executive Officer | Jan 25 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | 78.54K | $3.54 | -$16.84K | Jan 11, 2017 | Grant | 166.27% | 125.78K | Chief Executive Officer | Jan 9 | — | View | |
| EYPT | pSivida Corp. | 30.00K | — | — | Dec 14, 2016 | Grant | — | 30.00K | — | Dec 12 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | -457.00 | $4.12 | -$1.88K | Nov 10, 2016 | Tax | -0.96% | 47.24K | Chief Executive Officer | Oct 25 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | 50.92K | — | — | Sep 30, 2016 | Grant | — | 50.92K | Chief Executive Officer | Sep 29 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | -457.00 | $5.40 | -$2.47K | Aug 12, 2016 | Tax | -0.95% | 47.70K | Chief Executive Officer | Jul 25 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | -4.54K | $0.68 | -$3.09K | May 2, 2016 | Tax | -0.98% | 458.84K | Chief Executive Officer | Apr 25 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | 541.71K | $0.63 | -$13.29K | Jan 27, 2016 | Grant | 199.39% | 813.38K | Chief Executive Officer | Jan 25 | — | View | |
| EYPT | pSivida Corp. | 30.00K | — | — | Dec 4, 2015 | Grant | — | 30.00K | — | Dec 3 | — | View | |
| LSTA | LISATA THERAPEUTICS, INC. | 20.00K | $1.40 | $27.92K | Aug 18, 2015 | Purchase | 8.35% | 259.54K | Chief Executive Officer | Aug 17 | — | View | |
| LSTA | NeoStem, Inc. | 80.00K | — | — | Jun 4, 2015 | Grant | 50.14% | 239.54K | Chief Executive Officer | Jun 2 | — | View | |
| LSTA | NeoStem, Inc. | -260.46K | $3.48 | -$454.26K | Jan 21, 2015 | Disposition | -31.76% | 559.54K | Chief Executive Officer | Jan 16 | — | View | |
| LSTA | NeoStem, Inc. | 820.00K | — | — | Jan 5, 2015 | Grant | — | 820.00K | Chief Executive Officer | Jan 5 | — | View | |
| LSTA | NeoStem, Inc. | — | — | — | Jan 5, 2015 | — | — | — | Chief Executive Officer | Jan 13 | — | View | |
| EYPT | pSivida Corp. | 30.00K | — | — | Dec 15, 2014 | Grant | — | 30.00K | — | Dec 11 | — | View | |
| — | AVANIR PHARMACEUTICALS, INC. | 28.90K | — | — | Feb 14, 2014 | Grant | 9.40% | 336.39K | — | Feb 12 | — | View | |
| EYPT | pSivida Corp. | 45.00K | — | — | Dec 20, 2013 | Grant | — | 45.00K | — | Dec 18 | — | View | |
| — | Regado Biosciences Inc | — | — | — | Aug 21, 2013 | — | — | — | President and CEO | Jan 13 | — | View | |
| — | AVANIR PHARMACEUTICALS, INC. | 38.90K | — | — | Feb 19, 2013 | Grant | 14.48% | 307.49K | — | Feb 14 | — | View | |
| EYPT | pSivida Corp. | 45.00K | — | — | Dec 14, 2012 | Grant | — | 45.00K | — | Dec 14 | — | View | |
| — | AVANIR PHARMACEUTICALS, INC. | 30.00K | — | — | Feb 17, 2012 | Grant | 12.57% | 268.59K | — | Feb 16 | — | View | |
| EYPT | pSivida Corp. | 45.00K | — | — | Dec 1, 2011 | Grant | — | 45.00K | — | Nov 29 | — | View | |
| — | AVANIR PHARMACEUTICALS, INC. | 30.00K | — | — | Feb 10, 2011 | Grant | 14.38% | 238.59K | — | Feb 8 | — | View | |
| EYPT | pSivida Corp. | 45.00K | — | — | Dec 10, 2010 | Grant | — | 45.00K | — | Dec 9 | — | View | |
| — | AVANIR PHARMACEUTICALS, INC. | 40.00K | — | — | Feb 22, 2010 | Grant | 23.73% | 208.59K | — | Feb 18 | — | View | |
| EYPT | pSivida Corp. | 45.00K | — | — | Nov 20, 2009 | Grant | — | 45.00K | — | Nov 19 | — | View | |
| — | AVANIR PHARMACEUTICALS | 60.00K | — | — | Feb 20, 2009 | Grant | 55.25% | 168.59K | — | Feb 19 | — | View | |
| EYPT | pSivida Corp. | 120.00K | — | — | Nov 20, 2008 | Grant | — | 120.00K | — | Nov 18 | — | View | |
| EYPT | pSivida Corp. | — | — | — | Jun 27, 2008 | — | — | 500.00 | — | Jan 13 | — | View | |
| — | AVANIR PHARMACEUTICALS | 56.91K | — | — | Feb 25, 2008 | Grant | 110.12% | 108.59K | — | Feb 21 | — | View | |
| EYPT | pSivida LTD | 750.00K | — | — | Nov 29, 2007 | Grant | — | 750.00K | — | Nov 27 | — | View | |
| EYPT | pSivida LTD | — | — | — | Sep 6, 2007 | — | — | — | — | Jan 13 | — | View | |
| EYPT | pSivida LTD | — | — | — | Aug 27, 2007 | — | — | 20.00K | — | Jan 13 | — | View | |
| — | AVANIR PHARMACEUTICALS | 44.25K | — | — | Mar 5, 2007 | Grant | 595.13% | 51.68K | — | Mar 1 | — | View | |
| — | AVANIR PHARMACEUTICALS | 7.43K | $15.59 | — | Feb 15, 2006 | Purchase | — | 7.44K | — | Feb 13 - Feb 14 | — | View | |
| — | AVANIR PHARMACEUTICALS | — | — | — | Aug 2, 2005 | — | — | — | — | Jan 13 | — | View |
Showing 71 results
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2026 Benzinga | All Rights Reserved